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Context: Cell-free nucleic acids circulating in plasma are considered a promising noninvasive tool
for cancer monitoring. BRAFV600E mutation in cell-free DNA (cfDNA) could represent an appro-
priate marker for papillary thyroid carcinoma (PTC).
Objective:Our aim is to investigate the role of BRAFV600E-mutated allele in cfDNA as a marker for
the diagnosis and follow-up of PTC.
Study Design: BRAFV600E allele was detected and quantified by an allele-specific real-time quan-
titative PCR assay in plasma from 103 patients affected by nodular goiter. As control populations,
we enrolled 49 healthy subjects and 16 patients with non-nodular thyroid diseases.
Results: The percentage of circulating BRAFV600Ewas significantly different between patients and
controls and throughout different cytological categories of ultrasound-assisted fine-needle aspi-
ration. Patients with a histopathological diagnosis of PTC showed a higher percentage of circu-
latingBRAFV600E (P .035) compared to thosewithbenignhistology. In 19patients, a secondblood
draw, taken 3–6months after surgery, showed a lower percentage ofBRAFV600E in cfDNA than the
presurgical sample (P  .001). The diagnostic performance of circulating BRAFV600E was assessed
by receiver operating characteristic curve analysis resulting in an area under the curve of 0.797. A
cutoff valuewas chosen corresponding tomaximumspecificity (65%) and sensitivity (80%).On this
basis, we evaluated the predictive value of BRAFV600E in Thy 3 patients with a resulting positive
predictive value of 33% and a negative predictive value of 80%.
Conclusions: The results of the present study provide encouraging data supporting the possibility
to take advantage of circulating BRAFV600E in the management of PTC. (J Clin Endocrinol Metab
98: 3359–3365, 2013)
Cancer accounts for 5–15% of all thyroid nodules, andmost of these carcinomas consist of differentiated
forms originating from follicular cells, mainly papillary
thyroid carcinoma (PTC) (1–3). Although 5–10% of lo-
coregional recurrences have been reported, these tumors
exhibit low biological aggressiveness and are associated
with a high rate of survival (4). As detailed in recent guide-
lines (5, 6), the treatment of PTC consists of thyroidec-
tomy followed, when appropriate, by radioactive iodine
(RAI) treatment with remnant ablation and adjuvant
aims. The patients are subsequently followed up bymeans
of ultrasound examination of the neck and measurement
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of the circulating thyroglobulin (Tg), thyroid-specific pro-
tein involved in the synthesis of thyroid hormones, in the
absence of anti-Tg-specific antibodies. In the minority of
patientswhere advanceddisease is identifiedRAI, surgery,
external radiotherapy, or chemotherapy may be used (7).
Based on these data, clinical effortsmust be undertaken
to avoid overtreatment of benign nodules and to identify
patients with potentially more aggressive disease to be
submitted to more stringent therapy and follow-up.
The diagnostic procedures of thyroid nodules include
ultrasound examination of the neck and cytological anal-
ysis of fine-needle aspiration (FNA) (8). Although ultra-
sound features may help in identifying thyroid nodules
harboring a differentiated carcinoma, FNAhas shown the
highest sensitivity and specificity (8). However, 20% of
nodules are diagnosed as indeterminate by cytological ex-
amination of FNA, and among this cytological category,
only 20–30% of the patients will have thyroid cancer (8).
Numerous recent studies assess the importance of inte-
grating the cytological results with the molecular analysis
of tumor markers (9–11). Somatic mutations in proto-
oncogenes, such as BRAF, KRAS, HRAS, NRAS, as well
as chromosomal alterations, such as RET/PTC rearrange-
ments and PAX/PPAR translocation, strongly suggest
the presence of malignancy (12), thus allowing us to select
patients to be submitted to surgery.
The identification of the molecular profile of tumor
cells may also have a prognostic value because numerous
studies seem to suggest that thyroid carcinomaspresenting
BRAFV600Emutation aremore aggressive andmetastasize
more frequently (13, 14).
In addition to cytological markers, tumor-specific
markers circulating inplasmamayrepresent anoninvasive
approach to provide important information in the setting
of both diagnosis and follow-up of PTC (15–17).
In fact, the study of circulating nucleic acids is a rela-
tively new but rapidly expanding field of medical research
(18). With the increasing demand for noninvasive ap-
proaches in the monitoring of cancer, circulating nucleic
acids have been considered a promising tool for many
clinical applications that can be achieved with the ad-
vances in technology and detectionmethods and improve-
ments in sensitivity and specificity of the detection.
BRAF somatic mutations have been reported in a wide
range of human cancers, with the highest frequency in
melanoma and thyroid cancer (19).
Because BRAFV600E is one of the most represented so-
matic mutations in PTC (20), it would be an appropriate
circulating marker for this disease.
Numerous studies have been published identifying
BRAFV600E somatic mutation in cytological samples of
thyroid cancer, whereas few data are available on the
possibility of reliably detecting BRAF-mutated DNA in
blood (21–23). Starting from the first results reported in
different types of cancer (21), BRAF positivity in blood
seems to significantly correlate to the presence of active
disease (22, 23).
The use of BRAFV600E as a circulating marker could
have several important clinical applications. In the diag-
nostic setting, it would integrate the data obtained from
cytological analysis of FNA, providing more complete in-
formation in particular cases such as multinodular goiters
where it is not possible to sample all nodules by FNA.
The availability of circulating markers could also play
an important role in the short- and long-term follow-up of
patients with previous thyroid cancer. Tg is an extremely
sensitive and reliable marker currently used for monitor-
ing persistent or recurrent disease in thyroid cancer (24).
However, in 25–30% of patients, the use of this marker is
hampered by the presence of Tg antibodies (25). More-
over, in patients that did not undergo a complete thyroid
ablation by surgical and RAI ablation, Tg is less powerful
in predicting persistency or recurrence of thyroid cancer
(5, 6). In these cases, alternative circulatingmarkerswould
have a great impact in the assessment of residual disease.
We therefore undertake thepresent study to explore the
possibility of using BRAFV600E mutation as a marker as-
sociated to cell-free DNA (cfDNA) for the diagnosis and
follow-up of PTC.
Patients and Methods
Patients
A total of 103 patients (74 females and 29 males; age range,
18–90 y; median, 55 y) admitted to the Endocrinology Unit of
Careggi Teaching Hospital because of nodular goiter were eval-
uated for the presence of BRAFV600E-mutated allele in cfDNA
circulating in plasma.
Patients were submitted to ultrasound-assisted FNA (US-
FNA) according to recent guidelines (8), and the cytological di-
agnoses were made in accordance with the 5 diagnostic groups
of the British Thyroid Association 2007, namely: Thy 1, nondi-
agnostic; Thy 2, non-neoplastic; Thy 3, follicular lesions; Thy 4,
suspicious of malignancy; and Thy 5, diagnostic of malignancy
(26). When more than 1 nodule was sampled by US-FNA in
multinodular goiters, the worst cytology was considered.
Our case study is composed as follows: Thy 2, n 27; Thy 3,
n  47; Thy 4, n  25; and Thy 5, n  4.
Surgical therapy was suggested to all the patients with Thy 3,
Thy 4, and Thy 5, and for 69 of them the histology report was
available. Histological examination demonstrated the presence
of differentiated thyroid cancer in 38 of 69 patients (all cancers
were papillary, 25 were classical variant, 11 were follicular vari-
ant, and 2 were minor variants). The 7 patients whose histology
was not available belong to the Thy 3 cytology group. Four of
them refused thyroidectomy and dropped out of the follow-up.
The remaining 3 patients did not undergo surgery because of age
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or comorbidities, and they are currently performing ultrasound
follow-up without evidence of evolution of the ultrasound
pattern.
In 22 subjects, paired formalin-fixed, paraffin-embedded
(FFPE) tissueswere available andwere analyzed forBRAFV600E.
Only FFPE tumor tissues containing at least 70% of tumor cells
were included.
Nineteenpatients affectedbyPTCwere submitted to a second
blood draw 3–6 months after surgery (mean, 4.4 mo; range,
2.7–6.4 mo). In this period, 12 patients also underwent RAI
treatment according to recent guidelines (5, 6). There was no
correlation between the percentage of circulating BRAFV600E
and the time from surgery or RAI treatment (data not shown).
As control populations, healthy subjects (n 49; 26 females
and 23 males; age range, 25–89 y; median, 53 y) and patients
withnon-nodular thyroiddiseases (NNT;n16;10 females and
6 males; age range, 23–77 y; median, 53 y) were enrolled in the
study. The NNT group includes patients affected by Graves’
disease (n 7), autoimmune hypothyroidism (n 5), and post-
operative hypothyroidism (n  4).
The research protocol was conducted in accordance with the
guidelines in the Declaration of Helsinki and approved by the
review board of the Department of Biomedical, Experimental,
and Clinical Sciences of the University of Florence; all of the
patients signed an informed consent.
DNA extraction
Peripheral blood (5ml)was collected in anEDTA tube, trans-
ported within 1 hour to the laboratory, and centrifuged twice at
4°C for 10minutes (1.600 and 14.000 relative centrifugal force).
Plasma aliquots were stored at 80°C before use. DNA was
extracted from 500 l plasma, using the QIAampDSP Virus Kit
(QIAGEN, Hilden, Germany) and RNAse digestion to prevent
RNA interference during assay reaction. DNA was extracted
from cell lines by the QIAamp DNA BloodMini kit (QIAGEN).
DNA from FFPE tissues was extracted using the FFPE Tissue kit
(QIAGEN).
Detection of BRAFV600E mutation in cfDNA and
FFPE tissue samples
For the detection ofBRAFV600E-mutated allele in cfDNA,we
used an allele-specific real-time quantitative PCR assay as pre-
viously described (27). Results are reported as percentage of
BRAFV600E-mutated allele over the wild-type allele.
Statistical analysis
Statistical analysis was carried out using the SPSS software
package 19.0 (SPSS, Chicago, Illinois). Statistical differences be-
tween qualitative results were assessed by the Fisher’s exact test,
whereas quantitative data were evaluated by the Student’s t test
for paired or unpaired data.
P values lower than .05 were considered statistically signifi-
cant. Receiver operating characteristic (ROC) curve analysis
based on Thy 4 plus Thy 5 cytologies (all positive for carcinoma
at histology) and healthy subjects was exploited for the assess-
ment of the accuracy and identification of a threshold. The
Youden Index (defined as Y sensitivity specificity 1) was
used for the selection of the optimal threshold value (cutoff
point) for the marker under study (28, 29).
Results
Quantitative evaluation of the results
BRAFV600E percentage in plasma: correlation with
cytology
Patients affectedbynodular thyroiddiseasewere sorted
on the basis of the cytological analysis, and the percentage
of BRAFV600E in cfDNAwas compared to that of healthy
subjects and patients with NNT (Figure 1).
The percentage ofBRAFV600E in cfDNAwas 1.7 0.3
in healthy subjects and 6.4  3.1 in patients with NNT
(Figure 1).
Compared to healthy subjects, the percentage of circu-
latingBRAFV600Ewas significantly higher in patientswith
Thy 3 (18.7  4.4; P  .001) and with Thy 4 plus Thy 5
nodules (27.1  6.7; P  .001).
Control subjects affected by NNTs had a lower per-
centage ofBRAFV600E in plasma than Thy 3 patients (P
.026) and Thy 4/Thy 5 patients (P  .008).
Moreover, subjects with Thy 2 showed a lower per-
centage of circulating BRAFV600E alleles (8.9 3.7) than
Thy 4/Thy 5 patients (P  .022).
BRAFV600E percentage before and after surgery in
patients affected by thyroid cancer
A group of 19 patients diagnosed with PTC were sub-
mitted to an additional blood draw 3–6months after sur-
gery and after RAI treatment when appropriate. Circulat-
ing BRAFV600E percentage was significantly reduced in
the postsurgical blood draw (6.5 3.7 vs 43.2 8.9; P
.001) compared to presurgical samples (Figure 2).
BRAFV600E percentage in plasma: correlation with
histology
BRAFV600E percentage in cfDNA from patients with
benign lesions according to histology report (9.9 3.2%;
Figure 1. Percentage of BRAFV600E allele vs BRAF wild-type (WT) allele
(mean  SE) in cfDNA from patients belonging to different US-FNA
cytological categories (Thy 2, n  27; Thy 3, n  47; Thy 4  Thy 5,
n  29), healthy subjects (n  49), and patients with NNT (n  16).
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n 31) was significantly lower with respect to those with
histological evidence of PTC (23.7  5.4%; n  38; P 
.035) (Figure 3).
BRAFV600E percentage in cfDNA is higher in patients
affected by classical papillary carcinoma (n 25) than in
those with the follicular variant (n  11) (31.8  7.3 vs
9.4  6.8; P  .033).
Clinical penetrance of the measurement of plasma
BRAFV600E
ROCcurve analysiswas used to assess the performance
of circulating BRAFV600E determination in thyroid carci-
noma patients and healthy controls.
The area under theROCcurve for Thy 4/Thy 5 patients
(all positive at histological evaluation) vs healthy subjects
was 0.797 (Figure 4). According to this analysis, we could
define a cutoff value for BRAFV600E-mutated allele in
cfDNA to maximize the clinical sensitivity and specificity
of the test. The calculated cutoff value was 2.65%, cor-
responding to 65% sensitivity and 80% specificity.
Qualitative evaluation of the results
All the analyses previously performed using quantita-
tive data are repeated here fromaqualitative point of view
by means of the determined cutoff.
Qualitative evaluation of BRAFV600E in Thy 3
patients
Thepredictive valueofBRAFV600Ewasevaluated in the
Thy 3 group, because Thy 4 and Thy 5 cytology is highly
informative of the presence of thyroid cancer.
According to the chosen cutoff, 18 of 33 Thy 3 pa-
tients were positive for BRAFV600E variant. Fisher’s ex-
act test revealed that 6 of 9 (67%) histology-positive
samples were mutated in BRAF, whereas the same vari-
ant was found in only 50% (12 of 24) of histology-
negative patients (P  .458).
The resultingpositivepredictive valueandnegativepre-
dictive value for this group of patients were 33 and 80%,
respectively.
Figure 2. Percentage of BRAFV600E allele vs BRAF wild-type (WT) allele
in cfDNA before and 3–6 months after surgery in 19 patients with
histological diagnosis of PTC. Twelve patients were also submitted to
RAI.
Figure 3. Percentage of BRAFV600E allele vs BRAF wild-type (WT) allele
(mean  SE) in patients with histological diagnosis of PTC (n  38) or
benign nodules (n  31).
Figure 4. ROC curve derived from the univariate logistic analysis
corresponding to BRAFV600E percentage in cfDNA in Thy 4 plus Thy 5
cytologies (all positive for PTC at histology, n  29) and healthy
subjects (n  49). ROC curve parameters, are reported in the table at
the bottom of figure.
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Qualitative evaluation of BRAFV600E before and
after surgery in patients affected by thyroid
cancer
The qualitative evaluation of the results obtained in 19
patients who had a matched pair of blood samples col-
lected before and after surgery is illustrated in Figure 2.
Twelve of 17 (71%) patients were preoperatively positive
formutatedBRAFV600E and turnednegative after surgery.
Five patients that were positive before surgery confirmed
the same result in the second blood sample collected after
treatment. Among these patients, 3 showed a weak posi-
tivity and did not have clinical, serological, or instrumen-
tal evidenceof disease,whereas in2patients that remained
markedly positive, persistence of disease was highly prob-
able (incomplete resectionof the tumor in1 case and stable
detectable serum Tg in the other case).
The 2 patients who were negative for mutated
BRAFV600E before surgery remained negative after
treatment.
Qualitative evaluation of BRAFV600E percentage in
plasma: correlation with histology
When considering the different histological types of the
tumors,we found that the percentage of positive caseswas
higher in patients affectedby classical papillary carcinoma
(18 of 25, or 72%) than in subjects bearing the follicular
variant (6 of 11, or 54%; P  .446)
BRAFV600E in paired FFPE tissues and plasma
samples
Comparison of plasma and tissue results in the same
subjectwasobtained in22patients by evaluating results of
the percentage of BRAFV600E-mutated allele on the basis
of the above-reported cutoff value. A statistically signifi-
cant correlation was found when analyzing the concor-
dancebetweenplasmaand tissue samples byFisher’s exact
test (P  .006) (Table 1). Overall, 17 subjects obtained
concordant results on tissue as well as plasma, 6 resulting
wild-type and 11 showing the mutation in both samples.
Two mutated tissues did not find correspondence in
plasma DNA, whereas 3 subjects showed the BRAFV600E
mutation only in plasma.
Postsurgery Tg levels in PTC patients with BRAFV600E
evaluation both in plasma and tissue were always unde-
tectable; thus, this marker was not able to provide addi-
tional information in the cases of discordantBRAF status.
Discussion
The results of the present study suggest that circulating
BRAFV600E may be a helpful tool in the diagnosis and
follow-up of PTC.
US-FNA is extremely reliable in identifying the small
percentage (5–15%)of thyroid cancer amongmost benign
nodular lesions (8).However, in approximately20%ofall
US-FNA, cytological examination will not be informative
(Thy 3), and the patients will be submitted to surgery. In
this cytological category, only 20% of patients will be
proven to harbor a cancer that justifies surgical treatment.
The identification of somatic mutations in thyroid car-
cinoma and the possibility to detect their presence in cy-
tological samples improves the accuracy of US-FNA in the
Thy 3 group of patients (10, 11, 30). Among these bio-
molecular markers, BRAFV600E is the most common so-
matic mutation in PTC, accounting for 45–80% of all
genetic variants (19).
During the last 10years, researchers havebeen studying
cfDNA present in plasmawith great expectations on their
use as potential biomarkers for cancer and other patho-
logical conditions. cfDNA may derive from apoptotic or
necrotic cells and canbe released actively fromnormal and
diseased cells. Tumor-specific alterations, such as muta-
tions, can be found in cfDNA of tumoral origin. Methods
with high analytical sensitivity are essential for detecting
these specific alterations in a background of “normal”
cfDNA molecules (31).
Because the presence of circulating BRAFV600Ewas re-
ported in the blood of patients with different types of can-
cers including thyroid carcinoma (21), few evidenceswere
provided supporting its use in the diagnosis and follow-up
of this disease (22, 23). The presence of mutated
BRAFV600EDNAwas reported in 36%of a small series of
14 patients diagnosedwith PTC (23). Data obtained from
patients submitted to follow-up for PTC suggested a cor-
relation between the detection of circulating cell-free
BRAFV600E and the presence of active disease (22). At
variancewith our results andwith previous reports, recent
data failed to detect circulating BRAFV600E in 94 serum
samples from patients with PTC positive for the
BRAFV600E mutation in the tumor itself by using a quan-
titative PCR method (32). The use of assay reagents with
inadequate sensitivity and/or not optimized for plasma
samples in addition to uncontrolled preanalytical steps
Table 1. Comparison of BRAF V600E Detection in
Plasma and Corresponding FFPE Tissue Samples (P 
.006, Fisher’s exact test).
FFPE
Tissue
Plasma
TotalNegative Positive
Negative 7 3 10
Positive 1 11 12
Total 8 14 22
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can be the source of the discordant results on the mea-
surement of BRAFV600E-mutated allele in cfDNA. We
demonstrated that the percentage of BRAFV600E in
cfDNA increased progressively in a significant manner
across cytological categories, and it was higher in patients
with histologically confirmed thyroid cancer compared to
those with benign histology. The quantitative and quali-
tative analysis of circulating BRAFV600E in the same pa-
tients before and after treatment (surgery and possible
RAI) strongly indicates a causal relationship between cir-
culating BRAFV600E and the presence of thyroid cancer.
The clinical performance of circulating BRAFV600E in
thyroid cancer has, however, several intrinsic limits. Based
on data obtained in tissue samples, BRAFV600E DNA oc-
curs in 25–85% of thyroid cancer, depending on the pa-
tient populationand thehistological subtype (20), and this
will account for false-negative samples. Furthermore,
BRAFV600E somatic mutation is also present in non-
thyroid cancer, such as melanoma and colorectal adeno-
carcinoma, and circulating BRAFV600E might in these
cases be a possible source of false-positives for thyroid
cancer (19). However, it is worthy of notice that we dem-
onstrated a significant correlation between plasma and
tissue BRAF status in a subset of patients. Regarding dis-
cordant cases, BRAFV600E-mutated alleles detected in
plasma of patients with wild-type primary tumor may
have been derived from a portion of the biopsied tumor
that was not used for the tissue-based PCR, as already
reported by someother authors (33). PostsurgeryTg levels
in PTC patients of this group were always undetectable
and therefore did not provide additional information.
Keeping this information in mind, we demonstrated
that circulating BRAFV600E has an acceptable negative
predicting value for PTC in the Thy 3 cytology group, and
its detection may be associated to the molecular profile in
nodular tissues to avoid unnecessary surgery. In the diag-
nostic setting, the evaluation of circulating BRAFV600E
may be useful when multiple nodules are present. In these
patients a circulating marker, such as BRAFV600E, might
identify thyroid cancer within the whole pool of nodules,
whereas FNA will provide information only for the sam-
pled nodules, usually no more than 2.
After surgery or surgery plus RAI therapy, 5 patients
out of 17 remained positive for circulating BRAFV600E.
Among these patients, 2 showed a marked positivity, and
the persistence of disease was suspected. These results
seem to indicate that circulating BRAFV600E could be as-
sociatedwith the persistence of disease and are in linewith
the data obtained by Cradic et al (22).
It is worthy of note that the 2 patients in whom circu-
lating BRAFV600E was not detected before treatment re-
mained negative also at the post-treatment sampling.
Theonlymarker currently used in the follow-upof PTC
is Tg, which is extremely sensitive and reliable (24) but
may be less informative in some subsets of patients. This
is particularly true when technical pitfalls may interfere
with Tg assays. This is the case of anti-Tg antibody pos-
itivity that occurs in 25% of patients (25).
Other settings that reduce the predictive values of cir-
culating Tg are related to the type of treatment. In fact, Tg
is a marker of thyroid tissue but is not specific for neo-
plastic tissue, and its power in predicting cancer recur-
rence is limited when normal thyroid tissue is spared by
surgical therapy. In addition, recent guidelines limited in-
dications to RAI treatment (5, 6), and in these patients the
presence of normal thyroid tissue belittles the use of Tg. In
all these cases, circulatingBRAFV600Emay become an ad-
ditional tool to monitor patients that have suffered with
PTC.
Few other circulating markers have been proposed so
far for the follow-up of PTC (15–17). Among these, the
detectionof circulatingTSHreceptormRNAhasprovided
extensive data. However, TSH receptor is, like Tg, a
marker of normal thyroid tissue, and it will be very inter-
esting to assess whether there is a correlation between
circulating BRAFV600E and TSH receptor mRNA and
whether the combination of these 2 biomolecularmarkers
will have a synergistic effect.
Finally, circulating BRAFV600E could be useful in se-
lecting patients with advanced thyroid carcinoma to be
treatedwith newly developed small molecule inhibitors of
the activity of BRAFV600E (eg, PLX4720, PLX4032 and
sorafenib) that are promising approaches to the treatment
of these patients (34–36).
When analyzed with respect to histological subtypes,
we found that circulating BRAFV600E was more frequent
in conventional papillary carcinomas (72%) than in the
follicular variant (54%). These results are in agreement
with the data reported in tissues (37).
In summary, the results of the present study provide
encouraging data supporting the possibility to take ad-
vantage of circulating BRAFV600E in the management of
PTC. However, additional studies will be required before
circulating BRAFV600E could be widely used in clinical
settings.
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